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Introduction
Inorganic arsenic (iAs) is a toxic and carci-
nogenic metalloid that is found in ground-
water, soil, food, and air (Welch et al. 1988). 
Experimental and epidemiological studies 
support the role of chronic iAs exposure in 
arsenic toxicity (Hughes 2002). In partic-
ular, iAs exposure has been associated with 
cancer [International Agency for Research 
on Cancer (IARC) 2004], cardiometabolic 
disease (Moon et al. 2012; Navas-Acien et al. 
2008), and kidney disease (Peters et al. 2014; 
Zheng et al. 2015). After entering the body, 
iAs undergoes two sets of reduction and 
methylation reactions to a trivalent state and 
oxidation to a pentavalent state, producing 
monomethylarsonate (MMA) and then 
dimethylarsinate (DMA) (Hughes 2002). 
The arsenic species iAs, MMA, and DMA 
excreted via urine serve as biomarkers of 
arsenic metabolism (Vahter 1999). Although 
the pathways of arsenic toxicity have not 
been completely established, trivalent arsenic 
metabolites have been implicated in arsenic-
related toxicity via mechanisms including 
epigenetic regulation, cytotoxicity, inter-
fering with DNA repair, and oxidative stress 
(Hughes 2002).
More research is needed to understand 
the mechanisms of arsenic toxicity, particu-
larly given its systemic physiological effect 
on multiple organs. Arsenic toxicity may be 
better understood by investigating differences 
in response to arsenic; arsenic metabolism 
and patterns of arsenic methylation are 
subject to inter-individual variation and 
may be influenced by genetic susceptibility, 
age, sex, nutrition, route of exposure, and 
other risk factors (Concha et al. 2002; Vahter 
1999). The proportion of variation explained 
by genetic determinants (heritability) range 
from 50% to 53% for iAs%, 16% to 50% 
for MMA%, and 33% to 63% for DMA% 
(Chung et al. 2002; Gao et al. 2015). 
Association studies have shown the involve-
ment of single nucleotide polymorphisms 
(SNPs) in the arsenic (III) methyltransferase 
gene AS3MT, which encodes a major enzyme 
in biotransformation of iAs to MMA and 
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Background: Metabolism of inorganic arsenic (iAs) is subject to inter-individual variability, which 
is explained partly by genetic determinants.
oBjectives: We investigated the association of genetic variants with arsenic species and principal 
components of arsenic species in the Strong Heart Family Study (SHFS).
Methods: We examined variants previously associated with cardiometabolic traits (~ 200,000 from 
Illumina Cardio MetaboChip) or arsenic metabolism and toxicity (670) among 2,428 American 
Indian participants in the SHFS. Urine arsenic species were measured by high performance liquid 
chromatography–inductively coupled plasma mass spectrometry (HPLC-ICP-MS), and percent 
arsenic species [iAs, monomethylarsonate (MMA), and dimethylarsinate (DMA), divided by their 
sum × 100] were logit transformed. We created two orthogonal principal components that summa-
rized iAs, MMA, and DMA and were also phenotypes for genetic analyses. Linear regression was 
performed for each phenotype, dependent on allele dosage of the variant. Models accounted for 
familial relatedness and were adjusted for age, sex, total arsenic levels, and population stratifica-
tion. Single nucleotide polymorphism (SNP) associations were stratified by study site and were 
meta-analyzed. Bonferroni correction was used to account for multiple testing.
results: Variants at 10q24 were statistically significant for all percent arsenic species and principal 
components of arsenic species. The index SNP for iAs%, MMA%, and DMA% (rs12768205) 
and for the principal components (rs3740394, rs3740393) were located near AS3MT, whose gene 
product catalyzes methylation of iAs to MMA and DMA. Among the candidate arsenic variant 
associations, functional SNPs in AS3MT and 10q24 were most significant (p < 9.33 × 10–5).
conclusions: This hypothesis-driven association study supports the role of common variants in 
arsenic metabolism, particularly AS3MT and 10q24.
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DMA (Agusa et al. 2009; Rodrigues et al. 
2012; Schläwicke Engström et al. 2009). 
More recently, genome-wide association 
studies (GWAS) in Bangladesh showed 
the association of AS3MT variants with 
MMA% and DMA% (Pierce et al. 2012). 
Additionally, because kidney disease, type 2 
diabetes, and other cardiometabolic diseases 
have been associated with arsenic exposure, 
genes associated with metabolic traits may be 
relevant determinants of arsenic species.
U.S. Environmental Protection Agency 
(EPA) regulations state a maximum arsenic 
contaminant level in drinking water of 
10 μg/L. In 2001, the U.S. EPA Regional 
Tribal Program estimated that 16.5% of 
tribally owned community water systems 
had at least one source with arsenic levels 
> 10 μg/L, similar to other rural and suburban 
communities around the United States, 
especially in the West, the Midwest, and the 
Northeast (Navas-Acien et al. 2009). In this 
study, we characterized the genetic archi-
tecture of arsenic metabolism in extended 
American Indian families from Arizona, 
Oklahoma, and North and South Dakota. 
Our objective was to replicate previous studies 
and to find novel associations of common 
variants with markers of arsenic metabolism, 
which can highlight biological pathways 
that influence arsenic toxicity and related 
diseases. In addition, because the evaluation 
of arsenic metabolism is complex—being 
based on three interrelated biomarkers that 
sum to 100% (iAs%, MMA%, DMA%)—we 
used a relatively novel method to summarize 
 inter- individual variability in orthogonal 
urine arsenic species patterns using principal 
 components analysis (PCA).
Methods
Study Population
The Strong Heart Family Study (SHFS; http://
strongheart.ouhsc.edu/) is a large, multigen-
erational cohort recruited from the Strong 
Heart Study (SHS), an ongoing population-
based study conducted in 13 American Indian 
tribes/communities in Arizona, Oklahoma, 
and North and South Dakota. Details of the 
study design have been described previously 
(Lee et al. 1990; North et al. 2002). Briefly, 
families were eligible if they had a core sibship 
consisting of 3 original SHS participants and 
≥ 5 additional living family members including 
3 original SHS participants. The baseline visit 
was conducted in two phases; ~1,000 partici-
pants had their baseline visit in 1998–1999, 
and > 2,500 participants had their baseline 
visit in 2001–2003. Our study was restricted 
to 2,428 participants who were free of 
diabetes at the baseline visit, had urine arsenic 
species measured at baseline, were geno-
typed (MetaboChip and custom panel), and 
passed genotyping quality control, which is 
described in detail below. The SHFS protocols 
were approved by the Indian Health Service 
(https://www.ihs.gov) Institutional Review 
Board, by the Institutional Review Boards 
of the participating institutions, and by the 
participating American Indian tribes. Informed 
consent was obtained from all participants.
Arsenic Measurements
Total urine arsenic and arsenic species concen-
trations were measured in spot urine samples 
collected on the morning of the baseline 
visit. The samples were frozen and stored at 
–70°C. Total urine arsenic was determined 
using inductively coupled plasma mass 
spectrometry (ICP-MS), and arsenic species 
concentrations were determined using high 
performance liquid chromatography–ICP-MS 
(HPLC-ICP-MS) (Scheer et al. 2012). The 
inter-batch variability was monitored by 
obtaining replicate measurements of three 
urine reference materials with certified arsenic 
levels of 20.3 μg/L [National Institute of 
Standards and Technology (NIST) Standard 
Reference Material (SRM) 2669 I], 50.2 μg/L 
(NIST SRM 2669 II), or 119 μg/L [National 
Institute for Environmental Studies (NIES) 
Certified Reference Material (CRM) 18]; the 
coefficients of variation (CVs) ranged from 
3.8% to 14.4%, with an overall mean CV 
of 7.9% (n = 46) (see Table S1). The limit 
of quantitation for total arsenic and arsenic 
species was 0.10 μg/L. A total of 221 samples 
were below the limit of quantitation for iAs 
(9.1%), 63 samples were below the limit of 
quantitation for MMA (2.6%), and 1 sample 
was below the limit of quantitation for DMA 
(< 0.1%). The arsenic species levels below the 
limit of quantitation were imputed as the limit 
of quantitation divided by the square root of 
2 (0.07 μg/L). Because the lab assay included 
oxidization, the penta valent and trivalent 
species were indistin guishable. The percentage 
of each arsenic species (iAs%, MMA%, 
DMA%) was calculated as the relative propor-
tion of the species to the sum of all three 
arsenic species.
SNP Genotyping
DNA was extracted from blood specimens 
obtained at the baseline visit using organic 
solvents (North et al. 2003) and was geno-
typed according to Illumina protocol (Voight 
et al. 2012) using the Illumina Cardio-Metabo 
DNA Analysis BeadChip (MetaboChip), 
which contains 196,725 markers. These 
markers were selected based on a large-scale 
meta-analysis for cardiometabolic traits such 
as coronary artery disease and type 2 diabetes. 
Approximately one third of the MetaboChip 
SNPs consist of replication targets, and 
nearly two thirds are located in fine mapping 
regions, including AS3MT and other genes in 
the 10q24 region. Before genotyping quality 
control, nonautosomal and monomorphic 
markers were removed. Genotyping incon-
sistencies (Mendelian errors) were removed 
using Preswalk, a PEDSYS-compatible 
(Dyke 1996) version of Simwalk2 (Sobel 
et al. 2002), and allele frequency estimation 
and Hardy–Weinberg equilibrium (HWE) 
were estimated using Sequential Oligogenic 
Linkage Analysis  Routines (SOLAR) 
(Blangero and Almasy 1996). Family-based 
imputation was performed using a PEDSYS-
compatible version of Merlin (Abecasis et al. 
2002). Participants were excluded if the 
genotyping call rate was < 95% (n = 3). The 
SNP exclusion criteria included a call rate 
< 98% or no data (n = 33,604), not auto-
somal (n = 250), monomorphic (n = 158), 
HWE p < 1 × 10–5 (n = 1,519), and minor 
allele frequency (MAF) < 0.01 (n = 40,219). 
As a result, there were 120,975 common 
variants used in the analysis. Pairwise correla-
tions (r 2) between markers were calculated 
to estimate linkage disequilibrium (LD). A 
custom panel was used to genotype loci that 
were associated with arsenic traits in previous 
studies that were not already genotyped on the 
MetaboChip. A total of 670 arsenic candidate 
SNPs from 55 candidate genes (see Table S2) 
were genotyped. SNPs were assessed for assay 
inconsistencies and for whether they were 
monomorphic in the sample. Samples were 
also assessed for genotyping errors using a call 
rate < 95%, mismatch between genotyped and 
reported sex, outliers in identity by descent 
(IBD) clustering, or outliers in PCA. There 
were no SNPs that failed quality control.
Statistical Analysis
Percent arsenic species were logit transformed 
to approximate a normal distribution. Because 
percent arsenic species are interdependent, 
we also used PCA to summarize orthogonal 
dimensions of inter-individual variability 
in urine arsenic species patterns using the 
covariance structure of the arsenic species. 
Association analyses of 2,428 participants 
using MetaboChip SNPs and arsenic candi-
date SNPs were performed. All traits were 
modeled using linear regression of allele dosage 
at each SNP and were adjusted for age at 
baseline, sex, total arsenic levels, and principal 
components for population stratification. An 
additive SNP effect was assumed. All analyses 
were stratified by study region and accounted 
for familial relatedness using SOLAR. An 
inverse-variance-weighted meta-analysis of 
the stratified associations was performed 
using METAL (Willer et al. 2010). The 
MetaboChip-wide significance threshold was 
adjusted for multiple testing using Bonferroni 
correction (0.05/120,975 = 4.13 × 10–7). 
Because the Bonferroni method would over-
correct for multiple testing in the presence of 
Genetics of arsenic metabolism biomarkers
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LD (Nyholt 2004), the suggestive threshold 
was calculated for the effective number of 
SNPs accounting for LD using SOLAR 
(0.05/64374.85 = 7.77 × 10–7). Similarly for 
the arsenic candidate SNPs, the Bonferroni-
corrected s ignif icance threshold was 
9.33 × 10–5, and the LD-corrected significance 
threshold was 9.1 × 10–5. Association analysis 
conditioned on the index SNP, the most statis-
tically significant, informative SNP at the locus, 
was also performed using SOLAR. Simple 
linear regression analysis and stratification by 
sex were also performed for the arsenic traits 
as secondary analyses. All descriptive analysis 
was performed using R (version 3.2.2; R 
Foundation for Statistical Computing).
Results
The median [interquartile range (IQR)] for 
the sum of inorganic and methylated arsenic 
species was 6.6 (3.9–11.6) μg/L. Urine arsenic 
concentrations were higher in participants 
from Arizona than in participants from 
Oklahoma and North and South Dakota 
(Table 1). For arsenic metabolism, the 
median (IQR) was 9.8 (6.4–14.0) for iAs%, 
13.9 (10.5–17.7) for MMA%, and 75.6 
(68.6–81.6) for DMA%, with some variability 
across study regions (highest iAs% in Arizona, 
highest MMA% in North and South Dakota, 
and highest DMA% in Oklahoma). The vari-
ability in iAs%, MMA%, and DMA% can 
be summarized in two principal components. 
Principal component 1 (PC1) explained 
86.1% of the variance in arsenic species 
and reflected higher iAs% and MMA% and 
lower DMA% (Table 2). PC2 explained the 
remaining 13.9% of variance in arsenic species 
and reflected higher iAs% and lower MMA% 
independent of DMA% (Table 2).
The 10q24 region was statistically signifi-
cantly associated with all logit-transformed 
percent arsenic species using the MetaboChip 
SNPs (Figure 1). The index SNP rs12768205 
(G > A) in AS3MT was consistently associ-
ated with percent arsenic species (positively 
with iAs% and negatively with MMA% and 
DMA%) and principal components (nega-
tively with PC1 and positively with PC2) 
(Table 3; see also Tables S3–S7). For PC1, 
SNPs in 10q24 passed the MetaboChip-
wide alpha threshold, and the index SNP 
rs3740394 (A > G) in AS3MT was also asso-
ciated with DMA% (Table 3). An intronic 
SNP, rs3740393 (C > G), in AS3MT was 
the top SNP for PC2 and was also signifi-
cantly associated with MMA%, DMA%, and 
PC1 (Table 3). Other SNPs within the LD 
block with pairwise correlation r 2 > 0.80 of 
the index SNP (104.62–104.65 mb) were 
statistically significantly associated with PC1 
and PC2 (Figure 2; see also Tables S6 and 
S7). Quantile-quantile plots (see Figure S1), 
Manhattan plots (see Figures S3–S7) and 
top SNP associations (see Tables S2–S6) 
for MetaboChip SNPs are presented in the 
supplemental material. Association analyses 
in the 10q24 region conditioned on the index 
SNP did not yield any statistically significant 
independent associations that were not in LD 
(see Figures S8 and S9).
Similar to the MetaboChip SNP associa-
tions, the only region that passed the multiple 
testing correction among the arsenic candi-
date SNPs was 10q24 (Table 4; see also 
Tables S8–S12). A total of nine SNPs were 
associated with at least one trait; five SNPs 
were intronic, and four SNPs had known 
functional changes. There were two coding 
SNPs (rs11191439, T > C in AS3MT; rs4925, 
G > T in GSTO1) that alter the amino acid 
sequence and two SNPs (rs7911488, A > G 
in USMG5; rs2297235, A > G in GSTO2) 
that were located in the 3´ untranslated 
region in the mRNA after a stop codon. The 
quantile-quantile plots (see Figure S2) and 
top SNP associations (see Tables S8–S12) for 
the arsenic candidate SNPs are presented in 
the supplemental material. Secondary analyses 
including the unadjusted models, minimally 
adjusted models, models stratified by sex, 
and the conditional models for the arsenic 
traits did not yield any additional significant 
SNP associations.
The index SNP rs12768205 explained 
1–15% of the heritability of the trait: iAs% 
(Arizona 5.8%, Oklahoma < 0.1%, North 
and South Dakota 1.1%), MMA% (Arizona 
10.1%, Oklahoma 0.5%, North and South 
Dakota 2.2%), DMA% (Arizona 12.1%, 
Oklahoma 14.8%, North and South Dakota 
3.4%). At rs12768205, each copy of the 
variant allele G had a separation in the distri-
bution of percent arsenic species (Figure 3). 
The variant genotype GG, compared to geno-
types GA and AA, had iAs% and MMA% 
distributions that were shifted towards higher 
percentages and a DMA% distribution that 
was shifted towards lower percentages. There 
was also a clear additive effect with each 
copy of the variant allele G for each percent 
arsenic species. The pattern of percent arsenic 
species by rs12768205 was similar when 
stratified by study region. The distribution 
of percent arsenic species by the index SNP 
genotypes for PC1 (see Figure S10) and 
PC2 (see Figure S11) are presented in the 
 supplemental material.
Discussion
We examined common variants (MAF > 1%) 
in arsenic metabolism among American 
Indians as measured by logit-transformed 
iAs%, MMA%, DMA%, and principal 
components of logit arsenic species (PC1, 
PC2). The variants evaluated were available on 
the MetaboChip with nearly 200,000 markers 
supplemented with a custom panel of 670 
candidate SNPs for arsenic metabolism and 
toxicity. Locus 10q24 was consistently asso-
ciated with the arsenic phenotypes, similar 
to previous genome-wide association studies 
(GWAS) among unrelated individuals in 
Bangladesh and Vietnam (Agusa et al. 2009; 
Pierce et al. 2012; Rodrigues et al. 2012) and 
with a linkage peak in chromosome 10 among 
SHFS participants (Gribble et al. 2015). In 
our study, AS3MT SNPs produced signifi-
cant estimates in the 10q24 locus, and the 
results suggest that common variants play a 
substantial role in the variation of percent 
arsenic species and principal components of 
arsenic species.
In AS3MT, rs12768205 was associated 
with iAs% (p = 8.27 × 10–8), MMA% (p = 
1.20 × 10–15), and DMA% (p = 5.90 × 10–24). 
The index SNPs for the principal components 
Table 1. Baseline characteristics of Strong Heart Family Study participants.
Characteristic Total Arizona Oklahoma
North and 
South Dakota p-Value
Number of participants 2,428 703 819 906
Mean age, years (SD) 35.2 (15.2) 30.9 (13.1) 38.8 (15.7) 35.3 (15.4) < 0.01
Number of females (%) 1,469 (60.5%) 438 (62.3%) 486 (59.34%) 545 (60.15%) 0.48
Arsenic levels < 0.01
Tertile 1 (0.21–4.73 μg/L) 804 (33.1%) 100 (14.2%) 357 (43.5%) 347 (38.3%)
Tertile 2 (4.74–9.35 μg/L) 799 (32.9%) 204 (29.0%) 293 (35.7%) 302 (33.3%)
Tertile 3 (9.37–176.6 μg/L) 825 (33.9%) 399 (56.7%) 169 (20.6%) 257 (28.3%)
Median iAs% (IQR) 9.78 (6.4–14.0) 10.8 (7.6–15.2) 8.2 (5.4–12.3) 10.1 (6.7–14.5) < 0.01
Median MMA% (IQR) 13.9 (10.5–17.7) 12.8 (10.0–16.2) 13.7 (10.3–17.8) 14.9 (11.5–18.5) < 0.01
Median DMA% (IQR) 75.6 (68.6–81.6) 75.2 (69.0–81.1) 77.2 (70.5–83.3) 74.3 (67.3–80.4) < 0.01
Mean PC1 (SD) 0.04 (12.21) 0.62 (12.05) –2.20 (11.64) 1.62 (12.54) < 0.01
Mean PC2 (SD) –0.01 (4.91) 1.59 (4.87) –0.70 (4.53) –0.63 (5.00) < 0.01
Notes: DMA%, percent dimethylarsinate; iAs%, percent inorganic arsenic; IQR, interquartile range; MMA%, percent 
monomethylarsonate; PC, principal component; SD, standard deviation.
Table 2. Summary of principal components of 
arsenic species.
Descriptive statistic PC1 PC2
Variance in arsenic species explained (%) 86.1 13.9
Standard deviation 12.21 4.91
Weight for iAs% 0.49 0.65
Weight for MMA% 0.32 –0.75
Weight for DMA% –0.81 0.10
Notes: DMA%, percent dimethylarsinate; iAs%, percent 
inorganic arsenic; MMA%, percent monomethyl arsonate; 
PC, principal component.
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were also located within AS3MT. AS3MT 
encodes the enzyme arsenic (III) methyl-
transferase, which is responsible for meth-
ylation of iAs to MMA/DMA. Prior studies 
show association with SNPs in LD with 
rs12768205 and arsenic species and skin 
lesions, clinical manifestations specific to 
high chronic arsenic toxicity (Gao et al. 2015; 
Pierce et al. 2012; Rodrigues et al. 2012). 
Recently, a population genetics study indi-
cated a positive selection force for AS3MT 
variants in Argentina exposed to high levels 
of arsenic in drinking water and character-
ized by elevated urine DMA% (Schlebusch 
et al. 2015). It is unknown whether this 
positive selection is specific to this commu-
nity or if it is present in other populations 
chronically exposed to arsenic. Our associa-
tion analysis results indicated that the same 
loci and possibly genes including AS3MT, 
CNNM2, and GSTO1 may be involved in 
arsenic metabolism. The distribution of 
percent arsenic species showed differentiation 
by rs12768205 genotype, suggesting that a 
functional SNP in LD may be a major causal 
factor in arsenic metabolism. Interestingly, 
previous GWAS of blood pressure and 
schizophrenia have found associations with 
AS3MT variants and the 10q24 locus (Cross-
Disorder Group of the Psychiatric Genomics 
Consortium 2013; Newton-Cheh et al. 2009), 
indicating a possible mechanism of arsenic 
metabolism and toxicity. It is also possible 
that AS3MT is involved in other metabolic 
processes beyond arsenic metabolism that have 
not yet been identified.
Among the candidate arsenic SNPs, 
functional and potentially causal variants in 
AS3MT were associated consistently with 
iAs%, MMA%, and DMA%. In particular, 
a potential candidate, the missense SNP 
rs11191439 (methionine→threonine) in 
AS3MT, is located within the LD block for 
rs12768205, the index SNP for percent arsenic 
species traits. Among the candidate arsenic 
SNPs, non-AS3MT genes also showed signals 
in our study. An upstream SNP at USMG5 
was associated with all arsenic traits. USMG5 
is a protein coding gene that is involved in 
skeletal muscle growth (Meyer et al. 2007; 
Zhao et al. 2014). The function of USMG5 
is unknown but may involve inter actions 
with ATP synthases (Meyer et al. 2007). 
Interestingly, phosphorylation of proteins 
encoded by USMG5 is known to be upregu-
lated by insulin in vivo in human skeletal 
cells (Meyer et al. 2007). In addition, mice 
exposed to 100 μg/L arsenite for 5 weeks 
showed impaired muscle function and mito-
chondrial myopathy compared with controls 
(Ambrosio et al. 2014). Confirmation, through 
fine mapping or sequencing as well as through 
functional analyses, is needed on the relevance 
of USMG5 to arsenic metabolism.
Figure 1. Regional association plot at 10q24 of percent arsenic species.
Index single nucleotide polymorphism (SNP) rs12768205 nearby associations according to human genome build 18 
for percent inorganic arsenic (iAs%) in top panel, percent monomethylarsonate (MMA%) in middle panel, and per-
cent dimethylarsinate (DMA%) in bottom panel. The solid red line is the MetaboChip-wide significance threshold at 
–log(4.13 × 10–7) or 6.38. The dashed orange line is the suggestive MetaboChip-wide linkage disequilibrium (LD) threshold 
at –log(7.77 × 10–7). Chr, chromosome.
Genetics of arsenic metabolism biomarkers
Environmental Health Perspectives • volume 125 | number 1 | January 2017 19
A coding variant (rs4925) at GSTO1 and 
an upstream variant (rs2297235) at GSTO2 
were associated with PC1. The SNP rs4925 
was also associated with PC2. The glutathione 
S-transferase omega (GSTO) family of genes 
are involved in transferring thiol functional 
groups and therefore are of importance in 
phase II metabolism of many xenobiotics. 
Because of their hypothesized role in oxida-
tive stress and carcinogenesis, polymorphisms 
in the GSTO family have been candidates 
for various cancers and late-onset Alzheimer 
disease (Piacentini et al. 2012; Lima et al. 
2008). In a population study based in 
Bangladesh, GSTO variants have been associ-
ated with urinary arsenic species (Rodrigues 
et al. 2012). Although the GSTO family of 
proteins is implicated in the arsenic reduction 
pathway (Hernández et al. 2008), we cannot 
infer causality from our candidate gene 
association results owing to the strong LD 
in the region. We also cannot discount the 
possibility that in addition to the strong LD, 
the genotype at one variant/gene can affect 
the expression at another. In fact, AS3MT 
variants may matter for gene expression in the 
SHS (Gribble et al. 2014). Additional mecha-
nistic and epidemiological research is needed 
to confirm the relevance of GSTO and other 
functional variants in arsenic metabolism 
and toxicity.
The biotransformation pathway for inor-
ganic arsenic is unresolved; prior biological 
evidence suggests that arsenic metabolism is 
mainly determined by reduction followed by 
oxidative methylation (Cullen and Reimer 
1989; Vahter and Concha 2001; Vahter 
1999). Our results from principal components 
analysis support this hypothesis. Because iAs% 
and MMA% are inversely related to DMA%, 
PC1 may represent the overall methylation 
to DMA. Because PC2 had an inverse rela-
tionship between iAs% and MMA% inde-
pendent of DMA%, PC2 may represent the 
first methylation step from iAs to MMA. In 
addition, the development of arsenic-related 
chronic diseases may be related to reactive 
oxygen species and reactive nitrogen species 
caused by arsenic toxicity (Jomova et al. 2011; 
Jomova and Valko 2011; Shi et al. 2004; 
Valko et al. 2007). Metabolizing inorganic 
arsenic leads to damaging effects to most 
organs (Shi et al. 2004). An imbalance of 
reactive oxygen or nitrogen species exceeding 
the body’s physiological antioxidant defenses 
can lead to widespread tissue injury, organ 
dysfunction, and clinical disease via oxidative 
stress (Jomova et al. 2011; Valko et al. 2007). 
The genes associated with arsenic species 
and principal components of arsenic species 
in our analysis support this oxidative stress 
hypothesis (Jomova et al. 2011). In partic-
ular, previous studies showed that AS3MT 
and non-AS3MT proteins such as USMG 
and GSTO can reduce pentavalent arsenic 
and facilitate transfer of arsenic intermedi-
ates as well as antioxidant depletion within 
and between cells (Hughes 2002; Lefort et al. 
2009; Tanaka-Kagawa et al. 2003; Vahter and 
Table 3. Index MetaboChip SNPs of percent arsenic species and principal components of arsenic species.
SNP Chr Positiona Allele MAF Gene Location Trait
p-Value
iAs% MMA% DMA% PC1 PC2
rs3740393 10 104626645 C/G 0.17 AS3MT intron PC2 8.63 × 10–7 1.07 × 10–13b 2.71 × 10–23b 2.58 × 10–34b 1.56 × 10–8b
rs3740394 10 104624464 A/G 0.18 AS3MT intron PC1 1.27 × 10–4 4.66 × 10–7c 3.87 × 10–20b 2.19 × 10–38b 5.57 × 10–6
rs12768205 10 104637839 G/A 0.27 AS3MT intron iAs%, MMA%, DMA% 8.27 × 10–8b 1.20 × 10–15b 5.90 × 10–24b 1.15 × 10–29b 1.78 × 10–7b
Notes: Chr, chromosome; DMA%, percent dimethylarsinate; iAs%, percent inorganic arsenic; MMA%, percent monomethylarsonate; MAF, minor allele frequency; PC, principal compo-
nent; SNP, single nucleotide polymorphism.
aBase position according to human genome build 18.
bSignificant SNP associations (p < 4.13 × 10–7).
cSuggestive SNP associations (p < 7.77 × 10–7).
Figure 2. Regional association plot at 10q24 of principal components of arsenic species.
Index single nucleotide polymorphisms (SNPs) for principal components (PCs) (top panel PC1 rs3740394, bottom panel 
PC2 rs3740393) and nearby associations according to human genome build 18. The solid red line is the MetaboChip-wide 
significance threshold at –log(4.13 × 10–7) or 6.38. The dashed orange line is the suggestive MetaboChip-wide linkage 
disequilibrium (LD) threshold at –log(7.77 × 10–7).
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Concha 2001). These proteins may also lead 
to oxidative stress via mitochondrial dysregula-
tion from a buildup of free radicals (Lefort 
et al. 2009; Tanaka-Kagawa et al. 2003), and 
the ubiquity of mitochondrial function in 
all tissues may affect most organ systems and 
chronic diseases (Jomova et al. 2011; Valko 
et al. 2007).
This is the first large-scale study to assess 
markers of arsenic metabolism and common 
variants in a representative U.S. American 
Indian population sample; it is also one of 
only a few studies to evaluate genetic determi-
nants of arsenic metabolism in a population 
exposed to low to moderate levels of arsenic. 
The Strong Heart Family Study presents a 
rich family-based cohort with low limits of 
quantification and limited missing data for 
arsenic exposure, arsenic species, and other 
covariates. Another strength of this study is 
the consistency of the findings within our 
study with those in the existing literature. In 
our study, the index SNP rs12768205 located 
in the AS3MT gene was associated with iAs%, 
MMA%, and DMA%, and SNPs in LD with 
rs12768205 were associated with PC1 and 
PC2. AS3MT has been previously reported to 
influence arsenic traits, including total arsenic 
levels (Argos et al. 2011; Pierce et al. 2012). 
Although individual urine arsenic metabo-
lites are used in most cohort studies to assess 
arsenic metabolism, the pattern of arsenic 
metabolites in blood is different from that in 
urine, and it is unknown if the genetic deter-
minants for urine arsenic metabolism corre-
spond to the genetic determinants of arsenic 
metabolism as measured in blood (Goullé 
et al. 2005; Nixon and Moyer 1996; Tellez-
Plaza et al. 2013; Vahter 1999; Valentine et al. 
1979). In particular, although blood arsenic 
levels would be a more proximal biomarker of 
arsenic metabolism, they tend to be present at 
much lower levels that are difficult to detect 
by conventional spectrophotometric methods 
(Kristiansen et al. 1997). Furthermore, the 
few epidemiologic studies using blood arsenic 
measurements, conducted in populations 
exposed to high levels of arsenic in drinking 
water, have shown more consistent associa-
tions than urine arsenic measurements (Hall 
et al. 2006; Valentine et al. 1979). No studies, 
however, have evaluated the association of 
genetic variants with blood arsenic species. 
Future research is needed to evaluate whether 
the genetic variants associated with arsenic 
metabolism measured in urine are similar 
to those associated with arsenic metabolism 
measured in blood. Finally, PCA allowed us 
not only to reduce the number of dimensions 
but also to account for the interdependence of 
Table 4. Top Candidate SNPs of percent arsenic species and principal components of arsenic species.
SNP Chr Positiona Allele MAF Gene Location
p-Value
iAs% MMA% DMA% PC1 PC2
rs11191439 10 104638723 T/C 0.18 AS3MT coding 3.23 × 10–4 2.60 × 10–7b 2.89 × 10–19b 1.12 × 10–36b 7.54 × 10–7b
rs3740394 10 104634474 A/G 0.19 AS3MT intron 2.53 × 10–6b 7.55 × 10–7b 8.30 × 10–20b 2.83 × 10–38b 6.09 × 10–8b
rs3740390 10 104638480 C/T 0.20 AS3MT intron 1.76 × 10–8b 9.24 × 10–13b 8.63 × 10–23b 6.50 × 10–34b 0.99
rs11191453 10 104659852 T/C 0.20 AS3MT intron 6.48 × 10–7b 5.57 × 10–12b 2.18 × 10–21b 1.80 × 10–32b 0.34
rs4919694 10 104698978 T/C 0.18 CNNM2 intron 8.10 × 10–10b 4.74 × 10–7b 1.67 × 10–18b 9.67 × 10–36b 3.95 × 10–8b
rs7911488 10 105154089 A/G 0.25 USMG5 UTR 1.04 × 10–6b 6.54 × 10–8b 7.04 × 10–18b 3.57 × 10–31b 6.63 × 10–6b
rs4925 10 106022789 C/A 0.12 GSTO1 coding 0.02 0.11 1.55 × 10–3 4.60 × 10–6b 9.18 × 10–7b
rs1147611 10 106025258 G/T 0.19 GSTO1 intron 0.11 0.35 7.23 × 10–3 8.45 × 10–6b 0.27
rs2297235 10 106034491 A/G 0.12 GSTO2 UTR 0.08 0.20 4.58 × 10–3 1.67 × 10–5b 4.31 × 10–3
Abbreviations: Chr, chromosome; DMA%, percent dimethylarsinate; iAs%, percent inorganic arsenic; MMA%, percent monomethylarsonate; MAF, minor allele frequency; PC, principal 
component; SNP, single nucleotide polymorphism.
aBase position according to human genome build 18.
bSignificant SNP associations (p < 9.33 × 10–5).
Figure 3. Distribution of percent arsenic species by rs12768205 genotype.
Index single nucleotide polymorphism (SNP) rs12768205 for percent arsenic species principal components shows separation of distribution of percent inorganic arsenic (iAs%), percent 
monomethylarsonate (MMA%) and percent dimethylarsinate (DMA%) by genotype. Of the 2,428 participants, the distribution of genotypes is homozygous major AA (1,245), heterozygous 
AG (982), and homozygous minor GG (201).
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arsenic species so that PC1 and PC2 represent 
independent traits.
The analysis of MetaboChip SNPs 
allowed us to test hypothesis-driven variants 
because MetaboChip SNPs were chosen 
given prior evidence of their association with 
cardiometabolic diseases. In addition, we 
assessed SNPs that were previously associated 
with arsenic species and arsenic-related traits, 
which resulted in an investigation of SNPs 
with higher biological plausibility than typical 
GWAS. However, the use of MetaboChip 
SNPs also limited the ability to investigate 
novel SNP associations. Another limita-
tion is that the MetaboChip panel was built 
using results from European American and 
African American populations (Voight et al. 
2012). The SNP coverage and LD patterns 
may be different when extrapolated to other 
populations, although the use of MetaboChip 
has been characterized among populations 
with Asian and Mexican ancestry (Crawford 
et al. 2013). In addition, we were not able 
to test rare variants. Given the large statis-
tical significance and the high LD observed 
in the 10q24 locus, it is possible that rare 
functional variants may be causal. We were 
able to look at some low-frequency variants 
(MAF 1–5%) among the candidate genes, but 
genome sequencing data may be more useful 
in identifying putative causal SNPs. It is also 
possible that the multiple testing correction 
was too strict, and therefore, type II error 
may be present, particularly in regions of 
strong LD such as locus 10q24, limiting our 
ability to find variants with possibly weaker 
effects than the AS3MT variants. Although 
the SHFS has a relatively small sample size, 
particularly for a genetic association study, 
the strength of the associations supports the 
importance of investigating genetic variants 
of arsenic metabolism within a prospective 
American Indian cohort. Finally, given the 
low to moderate levels of arsenic exposure in 
Arizona, Oklahoma, and the Dakotas, the 
generalizability of our findings needs to be 
further assessed in other populations.
Conclusion
Association signals in AS3MT and surrounding 
genes in 10q24 are consistently associated 
with percent arsenic species and principal 
components of arsenic species. Furthermore, 
functionally annotated variants in 10q24 also 
show a strong relationship with the arsenic 
traits. The associated genes such as AS3MT 
and GSTO1/2 highlight oxidative stress as a 
possible mechanism in arsenic biotransforma-
tion and therefore in arsenic-related diseases. 
Given the high LD in the 10q24 region in 
populations throughout the world (Fujihara 
et al. 2010; Gomez-Rubio et al. 2010), and 
particularly among the American Indians in 
our study, further investigation in comparable 
populations and using low-frequency variants 
is needed to confirm our findings. Further 
knowledge of causal variation may highlight 
biological mechanisms that are related to 
arsenic metabolism, including methylation, 
and may contribute to the elucidation of 
possible mechanisms for arsenic toxicity and 
the development of chronic diseases including 
skin lesions, cancer, and cardiovascular disease.
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